Effect of tolvaptan on the prognosis of patients with hepatic ascites

摘要

Aim Despite accumulating evidence concerning the efficacy of tolvaptan in the treatment of body fluid retention or hyponatremia, the effect of tolvaptan on the prognosis of patients with hepatic ascites has not been fully investigated. Methods A total of 628 patients with hepatic ascites who were treated with diuretics (furosemide, spironolactone, or tolvaptan) between 2007 and 2017 were enrolled and divided into two groups: those who received tolvaptan (original tolvaptan group, n ?=?278) and those who did not (original control group, n ?=?350). The cumulative survival rates between the groups were compared and the factors associated with survival in patients with hepatic ascites were identified using a Cox regression analysis. In addition, propensity score matching was applied in patients who started conventional diuretics for new‐onset hepatic ascites after September 2013 (pre‐matching tolvaptan group, n ?=?177; pre‐matching control group, n ?=?63), and the cumulative survival rates were compared between the post‐matching tolvaptan and control groups. Results The survival rate was significantly higher in the tolvaptan group than the control group ( P ?=?0.005), and tolvaptan therapy was identified as an independent factor associated with survival (hazard ratio 0.721 for death relative to control, P ??0.001). The propensity score‐matched comparison also showed a significantly higher survival rate in the tolvaptan group ( n ?=?51) than in the control group (n?=?51) ( P ?=?0.009). Conclusions This study suggests that tolvaptan might improve the prognosis of patients with hepatic ascites.